Journal profile · Endocrinology & Metabolism
DIABETES OBESITY & METABOLISM
ISSN 1462-8902 · eISSN 1463-1326 · Wiley-Blackwell Publishing Ltd · ENGLAND · Monthly · Founded 1999
DIABETES OBESITY & METABOLISM: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 6.08; hybrid open access; APC about USD 5,380; median 72 days to acceptance (161 articles, last 24 months); community-reported acceptance: fairly easy; 954 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
DIABETES OBESITY & METABOLISM is published by Wiley-Blackwell Publishing Ltd and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Diabetes Treatment and Management, Diabetes Management and Research and Diabetes, Cardiovascular Risks, and Lipoproteins, together about 45.5% of its articles. Its main subfields are Endocrinology, Diabetes and Metabolism. (generated from OpenAlex topic counts and CAS ranking data)
Authors are reminded that Diabetes, Obesity and Metabolism is primarily a journal of pharmacology and therapeutics, focused mainly on human research relevant to patient care. The scope of the journal includes studies of pharmacokinetics and pharmacodynamics, cost-effectiveness, real world evidence of drug utilisation, safety and effectiveness, as well as conventional randomised controlled trials (phase I-IV studies). High-quality meta-analyses and systematic reviews that provide original information on treatment effects and safety are considered as original research papers. DOM also welcomes manuscripts which report clinical data relating to novel devices, Apps, glucose sensors and insulin pumps used to improve glycaemic control. Readership Diabetologists; Endocrinologists; Researchers and clinicians working on obesity; Nutritionists; Dieticians; Cardiologists; Podiatrists; Diabetes Educators; Diabetic Specialist Nurses Keywords Diabetes; diabetic; diabetology; obesity; obese; metabolism; endocrinology; clinical pharmacology; experimental pharmacology; lipid metabolism; therapeutics; therapies; diet; dietary; exercise; interventions; metabolic disease; endocrine disease; metabolic syndrome; bone metabolism; drug metabolism; endocrine dysfunction; preclinical pharmacology; pharmacokinetics; meta-analyses; drug safety; drug tolerability. Abstracting and Indexing Information Abstracts on Hygiene & Communicable Diseases (CABI) Academic Search (EBSCO Publishing) Academic Search Alumni Edition (EBSCO Publishing) Academic Search Premier (EBSCO Publishing) AgBiotech News & Information (CABI) AgBiotechNet (CABI) AGRICOLA Database (National Agricultural Library) Animal Breeding Abstracts (CABI) CAB Abstracts® (CABI) Current Contents: Clinical Medicine (Clarivate Analytics) Embase (Elsevier) Food Science & Technology Abstracts™ (IFIS) Global Health (CABI) Health & Medical Collection (ProQuest) Health Research Premium Collection (ProQuest) HEED: Health Economic Evaluations Database (Wiley-Blackwell) Horticultural Science Abstracts (CABI) Hospital Premium Collection (ProQuest) Journal Citation Reports/Science Edition (Clarivate Analytics) MEDLINE/PubMed (NLM) Nutrition Abstracts & Reviews Series A: Human & Experimental (CABI) ProQuest Central (ProQuest) PubMed Dietary Supplement Subset (NLM) Review of Aromatic & Medicinal Plants (CABI) Rural Development Abstracts (CABI) Science Citation Index Expanded (Clarivate Analytics) Soybean Abstracts Online (CABI) Sugar Industry
From the journal's Aims & Scope
Research area (LetPub): Endocrinology & Metabolism
Editor-in-chief Richard DonnellyPublisher website
Editorial board by country: none in mainland China; most named United Kingdom 4, Hong Kong, China 1, United States 1, Italy 1, Canada 1 (9 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Diabetes Treatment and ManagementMedicine22.6%
- Diabetes Management and ResearchMedicine13%
- Diabetes, Cardiovascular Risks, and LipoproteinsMedicine9.9%
- Pancreatic function and diabetesMedicine8%
- Metabolism, Diabetes, and CancerBiochemistry, Genetics and Molecular Biology5.9%
- Bariatric Surgery and OutcomesMedicine4.9%
- Hyperglycemia and glycemic control in critically ill and hospitalized patientsMedicine4.6%
- Diabetes and associated disordersBiochemistry, Genetics and Molecular Biology4.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Endocrinology & Metabolism | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Endocrinology & Metabolism | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Endocrinology & Metabolism | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEPubMedEmbaseCAB AbstractsCurrent ContentsPublisher website
Other: EBSCO, ProQuest, AGRICOLA
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 6.08LetPub ·
- Impact factor (publisher) 2025
- 6.1Publisher website ·
- CiteScore 2026-06
- 8.5LetPub ·
- CiteScore (publisher) 2025
- 8.5Publisher website ·
- SJR 2026-06
- 2.27LetPub ·
- SNIP 2026-06
- 1.52LetPub ·
- h-index
- 112LetPub ·
- h-index
- 188OpenAlex ·
- i10-index
- 4,203OpenAlex ·
- 2-year mean citedness
- 5.26OpenAlex ·
- Self-citation rate
- 8.2%LetPub ·
- Share of gold OA articles
- 54.12%LetPub ·
Volume
- Articles per year
- 727LetPub ·
- Articles per year (publisher) 2025
- 894Publisher website ·
- Downloads per year (publisher) 2025
- 3,434,073Publisher website ·
Articles by year OpenAlex count · 8,159 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 993 | 695 | 688 |
| 2025 | 954 | 658 | 5,413 |
| 2024 | 751 | 569 | 8,081 |
| 2023 | 472 | 389 | 6,795 |
| 2022 | 347 | 236 | 8,655 |
| 2021 | 344 | 197 | 9,204 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
72 daysMedian, submission to acceptance · P25–P75 48 days – 96 days
- Acceptance to online
- median 13 days (162 articles)
- Submission to online
- median 89 days
- Sample
- 161 articles with submission and acceptance dates (2,104 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 3–8 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Acceptance rate (publisher) 2025
- 18%Publisher website ·
- Submission to first decision 2025
- 2 daysPublisher website ·
- Submission to acceptance 2025
- 64 daysPublisher website ·
- Acceptance to publication 2025
- 15 daysPublisher website ·
- Peer review
- Open peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 5,380 / EUR 4,650 / GBP 3,810 | — | — | |
| Publisher website | Yes, amount not published | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted6, with length limits
- letterreviewed. They do not have an abstract. Letters should not exceed 1,200 words. They can include up to 2 small figures OR tables, and a mamain text ≤ 1,200 words
- letters to the editor(iv) Letters to the Editor The editors welcome correspondence relating to work that has recently been published in the journalLength not stated
- opinionon of the published literature. Shorter opinion pieces or those communicating novel hypotheses can be submitted as a Commentary (1,500 words maximum; no abstrac…main text ≤ 1,500 words
- original article(i) Original Article Original Article papers should provide substantial new analyses and be structured as followsLength not stated
- research letters(ii) Research Letters These are short, focused communications conveying original results from new researchLength not stated
- review articleno abstract; maximum of 20 references). Review articles should not normally exceed 5000 words and 120 references. They require a non-structured (250 wordmain text ≤ 5,000 words
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, Peer review, Preprints, Trial registration / reporting guidelines
- AI use Artificial Intelligence Generated Content
Artificial Intelligence Generated Content (AIGC) tools — such as ChatGPT and others based on large language models (LLMs) — cannot be considered capable of initiating an original piece of research without direction by human authors. They also cannot be accountable for a published work or for a research design, which is a generally held requirement of authorship, nor do they have legal standing or …
Source ↗Publisher website ·- Authorship Authorship
Please refer to the journal’s Authorship policy in the Editorial Policies and Ethical Considerations section for details on author listing eligibility.
Source ↗Publisher website ·- Conflicts of interest Conflict of Interest Statement
Authors will be asked to provide a conflict of interest statement during the submission process. For details on what to include in this section, see the ‘Conflict of Interest’ section in the Editorial Policies and Ethical Considerations section below. Submitting authors should ensure they liaise with all co-authors to confirm agreement with the final statement.
Source ↗Publisher website ·- Data availability Data Sharing and Data Accessibility
The journal encourages authors to share the data and other artefacts supporting the results in the paper by archiving it in an appropriate public repository. Authors should include a data accessibility statement, including a link to the repository they have used, in order that this statement can be published alongside their paper.
Source ↗Publisher website ·- Publication ethics Publication Ethics
COPE member Model summary
This journal is a member of the Committee on Publication Ethics (COPE). Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read Wiley’s Top 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines can be found here.
Source ↗Publisher website ·- Peer review Transparent Peer Review
Transparent peer review Model summary
Diabetes Obesity and Metabolism is participating in a scheme to improve Peer Review Transparency. We encourage all authors to opt in to transparent peer review (TPR) at the time of manuscript submission.
Source ↗Publisher website ·- Preprints Preprint Policy
Preprint policy: preprints accepted Model summary
Diabetes, Obesity and Metabolism will consider for review articles previously available as preprints. Authors may also post the submitted version of a manuscript to a preprint server at any time. Authors are requested to update any pre-publication versions with a link to the final published article.MANUSCRIPT CATEGORIES AND REQUIREMENTS
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The journal requires that clinical trials are prospectively registered in a publicly accessible database and clinical trial registration numbers should be included in all papers that report their results. Authors are asked to include the name of the trial register and the clinical trial registration number at the end of the abstract. If the trial is not registered, or was registered retrospectivel…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wiley-Blackwell Publishing Ltd
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Monthly
- Founded
- 1999
- ISSN
- 1462-8902
- Electronic ISSN
- 1463-1326
- Latest issue on the website
- Volume 28, Issue 10 (October 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
FAQ
Frequently asked questions about DIABETES OBESITY & METABOLISM
What CAS zone is DIABETES OBESITY & METABOLISM in?
In the 2025 upgraded edition of the CAS Journal Ranking, DIABETES OBESITY & METABOLISM is in Zone 2 of Medicine, and in Zone 2 of the minor category Endocrinology & Metabolism. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of DIABETES OBESITY & METABOLISM?
The latest impact factor listed by LetPub is 6.08; CiteScore 8.5, h-index 188.
How long does peer review take at DIABETES OBESITY & METABOLISM?
Based on the dates recorded on 161 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 72 days (interquartile range 48–96 days); authors report an average review time of 3–8 weeks; the community-reported acceptance is “Fairly easy”; the journal's website gives an acceptance rate of 18% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of DIABETES OBESITY & METABOLISM based?
Of the 9 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United Kingdom (4), Hong Kong, China (1) and United States (1). Counted from the institutions listed on the board page; for reference only.
Which databases index DIABETES OBESITY & METABOLISM?
According to LetPub and DOAJ records, DIABETES OBESITY & METABOLISM is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, PubMed, Embase, CAB Abstracts and Current Contents; that list has not been checked against each database.
Is DIABETES OBESITY & METABOLISM open access, and what is the APC?
DIABETES OBESITY & METABOLISM is a hybrid journal. For open-access publication: APC about USD 5,380.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .